Cystitis, Hemorrhagic
Ifosfamide
Mesna

Mesna

This program discusses mesna (sodium 2-mercapto-ethane sulfonate), a detoxifying agent employed to avert hemorrhagic cystitis in patients undergoing chemotherapy with high-dose cyclophosphamide or ifosfamide. The discussion centers on mesna’s distinctive mechanism of action wherein it undergoes initial inactivation to dimesna (mensa disulfide) within the bloodstream. Once filtered through the kidneys and subsequently excreted into the bladder, mesna undergoes reactivation. In the bladder, the reactivated mesna detoxifies acrolein, a urotoxic byproduct of ifosfamide and cyclophosphamide, thereby mitigating the risk of hemorrhagic cystitis. This course explores mesna’s indications, potential adverse effects, and contraindications. Moreover, the program extends its purview to off-label applications, pharmacokinetics, monitoring strategies, and clinical toxicology considerations, offering healthcare professionals a comprehensive understanding of mesna’s role in patient care. Adhering to the American Society of Clinical Oncology (ASCO) guidelines, the CME emphasizes each interprofessional team member’s pivotal role in managing hemorrhagic cystitis through mesna administration, ultimately contributing to enhanced patient outcomes and elevated care standards.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.